Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse

Lauritsen, K; Andersen, Bjørg Marit; Laursen, L. C.; Hansen, J.P. Hart; Havelund, Troels; Eriksen, J.; Rehfeld, Jens F.; Kjærgaard, J; Rask-Madsen, J

doi:10.1016/0016-5085(91)80009-x

Cited by 46 publications

(18 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…was numer ically better, but nonetheless comparable with the find ings of Lauritsen et al [6] with omeprazole 10 mg daily:…”

Section: Discussionsupporting

confidence: 75%

“…Omeprazole 20 mg for 3 days a week was previously seen to inhibit gastric acid secretion, but with a return to pretreatment values before the subsequent dose of the drug [14], This schedule nonetheless proved effective in reducing DU relapse, which was 23% after 6 months [6]. In order to simplify the therapy, we doubled the daily omeprazole dosage and reduced the therapeutic schedule from 3 days to 2 (i.e.…”

Section: Discussionmentioning

confidence: 99%

“…The problem of hypergastrinemia associated with the suppression of acid secretion was not taken into account in this trial, on the assumption that: (a) omeprazole lOmg/day and 20 mg at weekends cannot significantly increase serum gastrin concentration [6]; (b) high-dose omeprazole (40 mg/day) led to an increase in basal serum gastrin concentrations after 4 weeks, but no further in crease for up to 4 years [24]; (c) in one previous, hitherto unpublished experience with 198 DU subjects, 3 Interdis ciplinary Group for Ulcer Study (GISU) centers observed that fasting serum gastrin levels were not significantly higher at the end of a 6-month period, even in the group given omeprazole 20 mg daily: the increases detected were judged as clinically irrelevant, with single gastrin values over 200 pg/ml only in 2 cases and no cases with values over 300 pg/ml [unpubl. data].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Six Months of Omeprazole 20 mg Daily, 20 mg Every Other Day or 40 mg at Weekends in Duodenal Ulcer Patients: A Multicenter, Prospective, Comparative Study

Mario¹

1995

Digestion

View full text Add to dashboard Cite

We performed an open, prospective, randomized, three-cell, 6-month clinical trial on the prevention of duodenal ulcer (DU) relapse, comparing three omeprazole schedules, i.e. 20 mg daily, 20 mg every other day (e.o.d.) and 40 mg on Saturdays and Sundays (S/S). Diagnosis of either healed or relapsed DU was on an endoscopic basis. Follow-up visits were performed at 3-monthly intervals with endoscopy at the baseline, after 6 months and at every symptomatic relapse. Statistics: χ² test with standardized deviates, Yates’ corrected χ² test and analysis of variance (one-way). One hundred and fifteen patients were randomized to receive omeprazole 20 mg/day, 123 omeprazole 20 mg e.o.d. and 115 40 mg S/S. Twenty-eight dropped out (11,8 and 9, respectively). Demonstrated ulcer relapse rates were 5.7% with omeprazole 20 mg/day, 18.1% with 20 mg e.o.d. and 17.6% with 40 mg S/S (p = 0.0124, ‘per-protocol’ analysis). No clinically significant adverse effects were recorded. In conclusion, of the three schedules studied, omeprazole 20 mg/day proved the most effective maintenance treatment for healed DU.

show abstract

“…was numer ically better, but nonetheless comparable with the find ings of Lauritsen et al [6] with omeprazole 10 mg daily:…”

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Six Months of Omeprazole 20 mg Daily, 20 mg Every Other Day or 40 mg at Weekends in Duodenal Ulcer Patients: A Multicenter, Prospective, Comparative Study

Mario¹

1995

Digestion

View full text Add to dashboard Cite

show abstract

“…In the series of patients receiving long-term omeprazole treatment for peptic ulcer disease or reflux oesophagitis [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17], no adenomatous or neoplastic changes and no carcinoid tumours were observed. Out of 184 patients with ZES on long-term omeprazole therapy [18][19][20][21][22], only 4 were shown to have macro scopic lesions.…”

Section: Monitoring For Macroscopic Changesmentioning

confidence: 99%

“…To date, there are 15 studies reporting a total of 646 patients with severe peptic ulcer disease or reflux oesophagitis who have under gone regular gastric biopsies during continuous treatment with omeprazole, 10-120 mg daily, for periods of up to 5.5 years [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. In addi tion.…”

Section: Monitoring For Microscopic Changesmentioning

confidence: 99%

Is Endoscopy Helpful in Patient Monitoring?

McCloy

1992

Digestion

View full text Add to dashboard Cite

The safety issues involved in patients on long-term treatment with omeprazole will determine whether endoscopic monitoring is necessary. In a review of 646 patients who have undergone regular gastric biopsies during continuous treatment with omeprazole, 10-120 mg daily, for periods of up to 5.5 years, there were no overall patterns to the changes in gastric endocrine cells. Apparent gastric endocrine cell hyperplasia in 72% of patients correlated with the development of chronic atrophic corpus gastritis. The only macroscopic changes to be reported were endocrine tumours in 4 out of 184 patients on long-term omeprazole for Zollinger-Ellison syndrome, and at least 3 of these patients had multiple endocrine neoplasia (MEN) type 1 syndrome. In patients with other low acid states, such as pernicious anaemia or after gastric irradiation or gastric surgery, in which drug therapy is not a confounding factor, there is a very low risk of developing macroscopic lesions within the stomach, and endoscopic surveillance is not routine practice. In conclusion, upper gastrointestinal endoscopic monitoring to identify microscopic or macroscopic changes cannot be justified during at least the first 5 years of continuous treatment with omeprazole.

show abstract

Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events

Cohen¹

2001

Arch Intern Med

View full text Add to dashboard Cite

Optimal therapeutics depends on the availability of comprehensive information. However, the PDR contains only the limited dose information from package inserts. Because the PDR was originally developed as a promotional device, there is no mechanism by which all clinically relevant dose-response data or important postrelease discoveries are regularly and rapidly incorporated into it. Thus, a gap exists in the availability of current and comprehensive dose information for physicians. This article provides information on lower, effective doses for 48 major medications, with an extensive reference list-a compilation of low-dose information not previously published, to our knowledge, in the medical literature. Physicians must have a readily accessible source of current and complete dose-response information to individualize drug therapy and minimize the risks of ADEs.

show abstract

Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse

Cited by 46 publications

References 42 publications

Six Months of Omeprazole 20 mg Daily, 20 mg Every Other Day or 40 mg at Weekends in Duodenal Ulcer Patients: A Multicenter, Prospective, Comparative Study

Six Months of Omeprazole 20 mg Daily, 20 mg Every Other Day or 40 mg at Weekends in Duodenal Ulcer Patients: A Multicenter, Prospective, Comparative Study

Is Endoscopy Helpful in Patient Monitoring?

Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events

Contact Info

Product

Resources

About